Literature DB >> 2899189

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus.

J E Grundy1, S F Lui, M Super, N J Berry, P Sweny, O N Fernando, J Moorhead, P D Griffiths.   

Abstract

74 patients receiving cadaver kidney grafts were investigated prospectively for cytomegalovirus (CMV) infection. Among seropositive recipients CMV infection, especially symptomatic and disseminated infection, occurred significantly more frequently when kidneys came from seropositive than from seronegative donors. Since seropositive recipients can become infected with donor virus, the excess is probably accounted for by reinfection. This conclusion was supported by restriction enzyme typing of virus isolates from recipient pairs receiving kidneys from the same donor; proven reinfection with donor strain virus was significantly commoner than proven reactivation of recipient virus. Furthermore, symptoms occurred only in the proven reinfection group. Although the proportion of reinfections that caused symptoms was less than that seen in primary infections, prior natural infection with CMV clearly does not prevent symptomatic reinfection in seropositive recipients, a point which has profound implications for future vaccination strategies in renal allograft recipients and choice of donors.

Entities:  

Mesh:

Year:  1988        PMID: 2899189     DOI: 10.1016/s0140-6736(88)90685-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  Risk factors for viral reactivation following bone marrow transplantation.

Authors:  D Pillay; A Webster; H G Prentice; P D Griffiths
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study.

Authors:  D W Denning; C J Baker; N J Troup; L S Tompkins
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

Review 3.  Molecular biology of cytomegalovirus.

Authors:  V C Emery; P D Griffiths
Journal:  Int J Exp Pathol       Date:  1990-12       Impact factor: 1.925

4.  Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.

Authors:  M Van der Giessen; A P van den Berg; W van der Bij; S Postma; W J van Son; T H The
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

Review 5.  Human cytomegalovirus infection.

Authors:  J G Sissons; L K Borysiewicz
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

Review 6.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

Review 7.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  Opportunistic upper gastrointestinal infection in transplant recipients.

Authors:  S M Graham; J L Flowers; E Schweitzer; S T Bartlett; A L Imbembo
Journal:  Surg Endosc       Date:  1995-02       Impact factor: 4.584

9.  Cytomegalovirus disease in African-American kidney transplant patients.

Authors:  J McGee; V Mave; C L Yau; M Killackey; A Paramesh; J Buell; D P Slakey; L L Hamm; R Zhang
Journal:  Transpl Infect Dis       Date:  2012-12       Impact factor: 2.228

10.  Strain-specific neutralization of human cytomegalovirus isolates by human sera.

Authors:  M Klein; K Schoppel; N Amvrossiadis; M Mach
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.